Patents Issued in March 8, 2018
-
Publication number: 20180066020Abstract: The present invention is aimed for providing a novel peptide with a high drug efficacy and strong effect, a medicament or external preparation comprising it, specifically a prophylactic or therapeutic for dermatitis, rhinitis or alopecia, or a hair growth stimulant, a hair growing agent, an antipruritic or a skin-care product. The present invention achieved said aim by providing a cyclic peptide having an amino acid sequence expressed by the Formula I or a derivative thereof or a pharmaceutically acceptable salt thereof, wherein the amino acid sequence does not have a peptide bond that is not between the amino acids constituting the amino acid sequence.Type: ApplicationFiled: May 27, 2016Publication date: March 8, 2018Applicant: IGISU Co., Ltd.Inventors: Kyoko Endo, Yori Endo
-
Publication number: 20180066021Abstract: The present invention provides compounds that are antagonists of CXCR4 and methods for using the same for treatment of a clinical condition associated with CXCR4 activation. In particular, compounds of the invention include cyclic peptides. Compounds of the invention can be used to treat a variety of clinical conditions, including but not limited to, cancers, pulmonary fibrosis, HIV infection, rheumatoid arthritis, and other immune disorders. In addition, compounds of the invention can also be used in stem cell therapy.Type: ApplicationFiled: September 5, 2017Publication date: March 8, 2018Applicant: Mainline BiosciencesInventors: Junge Zhang, Liang Zeng Yan
-
Publication number: 20180066022Abstract: Methods and compositions are provided for intravitreally delivering a polynucleotide to cone photoreceptors. Aspects of the methods include injecting a recombinant adeno-associated virus comprising a polynucleotide of interest into the vitreous of the eye. These methods and compositions find particular use in treating ocular disorders associated with cone dysfunction and/or death.Type: ApplicationFiled: March 2, 2016Publication date: March 8, 2018Inventors: Thomas W. Chalberg, Jay Neitz, Maureen Neitz
-
Publication number: 20180066023Abstract: An approach of producing recombinant trimers that mimic native HIV-1 envelope trimers is developed. A recombinant protein forming the recombinant trimers encompasses a recombinant HIV-1 gp140 fused to a tag through a linker at C-terminus of the recombinant HIV-1 gp140. The linker is sufficiently long so that the tag is accessible for binding by a binding molecule bound on a solid matrix. After expressed in a cell, the recombinant protein is secreted into the culture medium and assembles into recombinant trimers therein. The recombinant trimers may be directly purified from the culture medium. Cleaved and uncleaved trimers from different clade viruses are produced.Type: ApplicationFiled: November 20, 2017Publication date: March 8, 2018Inventors: Venigalla B. RAO, Wadad ALSALMI
-
Publication number: 20180066024Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.Type: ApplicationFiled: April 10, 2017Publication date: March 8, 2018Applicants: Medigene AG, Ludwig-Maximilians-Universitaet, Universitaet zu KoelnInventors: Kerstin LUX, Hildegard BUENING, John NIELAND, Jorge BOUCAS, Mirko RITTER, Markus HOERER, Luca PERABO, Michael HALLEK
-
Publication number: 20180066025Abstract: Compositions having pesticidal activity and methods for their use are provided. Compositions include isolated and recombinant polypeptides having pesticidal activity, recombinant and synthetic nucleic acid molecules encoding the polypeptides, DNA constructs and vectors comprising the nucleic acid molecules, host cells comprising the vectors, and antibodies to the polypeptides. Nucleotide sequences encoding the polypeptides can be used in DNA constructs or expression cassettes for transformation and expression in organisms of interest. The compositions and methods provided are useful for producing organisms with enhanced pest resistance or tolerance. Transgenic plants and seeds comprising a nucleotide sequence that encodes a pesticidal protein of the invention are also provided. Such plants are resistant to insects and other pests. Methods are provided for producing the various polypeptides disclosed herein, and for using those polypeptides for controlling or killing a pest.Type: ApplicationFiled: September 12, 2017Publication date: March 8, 2018Inventors: Jessica Parks, Kira Bulazel Roberts, Rebecca E. Thayer
-
Publication number: 20180066026Abstract: Nucleotide sequences encoding YEP6 polypeptides are provided herein, along with plants and cells having reduced levels of YEP6 gene expression, reduced levels of YEP6 polypeptide activity, or both. Plants with reduced levels of gene expression of at least one YEP6 gene and/or reduced levels of YEP6 polypeptide activity that exhibit increased yield, increased staygreen, increased abiotic stress tolerance, or any combination of these, are provided. Methods for increasing yield, staygreen and abiotic stress tolerance in plants, by modulating YEP6 gene expression or activity, are also provided.Type: ApplicationFiled: December 3, 2015Publication date: March 8, 2018Inventors: KEVIN FENGLER, RAJEEV GUPTA, BAILIN LI, STEPHEN P MOOSE, BENJAMIN WEERS, WENGANG ZHOU
-
Publication number: 20180066027Abstract: The present invention relates to treatment of neuronal injury. The present invention discloses a novel use of an agent and a novel method for promoting neurite outgrowth and/or neural regeneration in CNS injuries. A novel mechanism of promoting neurite outgrowth by increasing the interaction of chondroitin sulphate proteoglycan (CSPG) to receptor protein tyrosine phosphatase sigma (RPTP?) is disclosed.Type: ApplicationFiled: September 28, 2017Publication date: March 8, 2018Applicant: UNIVERSITY OF HELSINKIInventors: Heikki RAUVALA, Mikhail PAVELIEV, Juha KUJA-PANULA, Ari ROUHIAINEN, Natalia KULESSKAYA
-
Publication number: 20180066028Abstract: The present disclosure relates to a collection of novel muteins derived from human ?1m (or a1m) polypeptide or a functional homologue thereof. The disclosure further refers to a ?1m mutein capable of specifically binding to one or more targets other than a target to which wild-type ?1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type ?1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of ?1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of a1m.Type: ApplicationFiled: August 18, 2017Publication date: March 8, 2018Applicant: TECHNISCHE UNIVERSITAET MUENCHENInventors: Arne SKERRA, Winfried MEINING, Evelyn EGGENSTEIN
-
Publication number: 20180066029Abstract: The invention discloses the use of an artificial protein for isolating a nucleosome, the nucleosome comprising a multiple-modified histone protein octamer, wherein the artificial protein comprises a first histone modification binding domain of 50 to 200 amino acids binding to a first histone modification, a second histone modification binding domain of 50 to 200 amino acids binding to a second histone modification, a linker of 5 to 50 amino acids connecting the first and the second histone modification binding domain, and an affinity tag. Further disclosed are a nucleic acid encoding the artificial protein, a host cell comprising the nucleic acid and a kit for isolating a nucleosome, the nucleosome comprising a multiple-modified histone protein octamer. Further disclosed is an in-vitro method for isolating a nucleosome having a first and a second histone modification.Type: ApplicationFiled: March 15, 2016Publication date: March 8, 2018Inventors: Albert JELTSCH, Goran KUNGULOVSKI, Rebekka MAUSER
-
Publication number: 20180066030Abstract: Methods of treating autoimmune diseases, such as vitiligo, by using compositions comprising DNA encoding a variant inducible heat shock protein 70 (HSP70i) having a mutation in the dendritic cell binding region thereof (HSP70i435-447) or an isolated variant gene product in the form of HSP70i with a modification in the dendritic cell activating region thereof (HSP70i435-447).Type: ApplicationFiled: October 24, 2017Publication date: March 8, 2018Inventors: I. Caroline Le Poole, Jose Alejandro Guevara, Andrew Zloza
-
Publication number: 20180066031Abstract: Provided herein are enzymatically-cleavable peptide amphiphiles and methods of use thereof.Type: ApplicationFiled: September 1, 2017Publication date: March 8, 2018Inventors: Handan Acar, James LaBelle, Matthew Tirrell
-
Publication number: 20180066032Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: November 16, 2017Publication date: March 8, 2018Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Publication number: 20180066033Abstract: Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.Type: ApplicationFiled: November 17, 2017Publication date: March 8, 2018Inventors: Lali K. MEDINA-KAUWE, Jessica SIMS, Michael TAGUAIM, Chris HANSON, Xiaojiang CUI
-
Publication number: 20180066034Abstract: The present disclosure provides chimeric antigen receptor polypeptides having antigen recognition domains for CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens, and polynucleotides encoding for the same. The present disclosure also provides for engineered cells expressing the polynucleotide or polypeptides. In some embodiments, the disclosure provides methods for treating diseases associated with CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens.Type: ApplicationFiled: February 26, 2016Publication date: March 8, 2018Inventors: Yupo MA, Kevin PINZ, Xun JIANG, Masayuki WADA, Kevin CHEN
-
Publication number: 20180066035Abstract: The present invention relates to chimeric antigen receptors (CARs) specific to ICAM-1 comprising I domain of the ?L subunit of human lymphocyte function-associated antigen 1 (LFA-1). The invention particularly relates to CARs comprising human I domains having different affinities (1 mM to 1 nM Kd) to ICAM-1. CAR T cells comprising human I domain having a low affinity (1 to 200 ?M Kd) to ICAM-1 can avoid targeting healthy tissues with basal ICAM-1 expression while simultaneously exhibiting increased potency and long-term efficacy against tumor tissues with high ICAM-1 expression. The present invention also relates to an adoptive cell therapy method for treating cancer by administering the CAR-T cells comprising human I domain to a subject suffering from cancer, whereby the CAR T cells bind to the cancer cells overexpressing ICAM-1 and kill the cancer cells.Type: ApplicationFiled: August 11, 2017Publication date: March 8, 2018Inventor: Moonsoo JIN
-
Publication number: 20180066036Abstract: Provided herein are specific CD40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD40L-associated disease or disorder. The CD40 receptor agonist proteins provided herein comprise three soluble CD40L domains and an Fc fragment. The CD40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.Type: ApplicationFiled: October 26, 2017Publication date: March 8, 2018Inventors: Oliver HILL, Christian GIEFFERS, Meinolf THIEMANN, Tim SCHNYDER
-
Publication number: 20180066037Abstract: The present invention is directed to transduced T cells expressing at least 100,000 molecules of human somatostatin receptor 2 (SSTR2), which improves PET/CT imaging sensitivity. The present invention is also directed to transduced T cells expressing SSTR2 and chimeric antigen receptor (CAR). In one embodiment, the CAR is specific to human ICAM-1 and the CAR comprises a binding domain that is scFv of anti-human ICAM-1, or an I domain of the ?L subunit of human lymphocyte function-associated antigen-1. In another embodiment, the CAR is specific to human CD19, and the CAR comprises a binding domain that is scFv of anti-human CD19. The present invention is further directed to using the above transduced T cells for monitoring T cell distribution in a patient by PET/CT imaging and/or treating cancer.Type: ApplicationFiled: August 11, 2017Publication date: March 8, 2018Inventor: Moonsoo JIN
-
Publication number: 20180066038Abstract: A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immunoglobulin gene is provided, as well as cells and targeting vectors for making the same.Type: ApplicationFiled: October 2, 2017Publication date: March 8, 2018Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
-
Publication number: 20180066039Abstract: The present invention relates to methods for treating hypercytokinemia and viral infections associated with hypercytokinemia using a mast cell stabilizing compound, optionally in combination with an antiviral agent. The invention further relates to compositions and dosage forms comprising mast cell stabilizing agents, optionally with an antiviral agent.Type: ApplicationFiled: September 7, 2017Publication date: March 8, 2018Inventors: Robin Parish Hyde-DeRuyscher, Nancy Harlan Hyde-DeRuyscher, Elicia Kristine Hyde-DeRuyscher
-
Publication number: 20180066040Abstract: The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.Type: ApplicationFiled: November 14, 2017Publication date: March 8, 2018Applicant: GENEURO S.A.Inventors: Herve PERRON, Reza FIROUZI, Patrick KÜRY, Raphaël FAUCARD, Alexandra MADEIRA, Julie JOANOU
-
Publication number: 20180066041Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae , which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.Type: ApplicationFiled: November 3, 2015Publication date: March 8, 2018Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Zehra VISRAM, Eszter NAGY, Jolanta Katarzyna LUKASIEWICZ
-
Publication number: 20180066042Abstract: For many diseases due to microbes or the like, proliferation of microbes themselves is a cause of a symptom. However, there were cases where a substance released by the microbes is a cause of a symptom. In such cases, when attempting to treat a disease with an antibody, it was necessary to obtain an antibody against an antigen that is a substance causing the disease. However, it was difficult to find the underlying substance causing the disease among substances released by the microbes. An antibody (polyclonal) binding to not only an antigen but also to a substance, which is secreted by the antigen and accelerates the deterioration of a symptom, is obtained by immunizing birds with a lysis solution produced from lysing microbial cells as an antigen. Further, an antibody obtained with a surface protein of a virus as an antigen is expected to inhibit an infection by a virus.Type: ApplicationFiled: November 9, 2017Publication date: March 8, 2018Applicants: Ostrich Pharma KK, Immortal Spirit LimitedInventor: Yasuhiro Tsukamoto
-
Publication number: 20180066043Abstract: The present invention provides an antigenic composition for use as a mycobacterial vaccine, said composition comprising (i) a first mycobacterial antigenic polypeptide, wherein said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 6, 12, 2, 18, 8, 10, 16, 4, or a fragment thereof having at least 50 consecutive amino acids thereof; or (ii) a first mycobacterial polynucleotide, wherein said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide, or wherein said first mycobacterial polynucleotide comprises a polynucleotide sequence selected from SEQ ID NO: 5, 11, 1, 17, 7, 9, 15, 3.Type: ApplicationFiled: August 8, 2017Publication date: March 8, 2018Applicant: The Secretary of State for HealthInventors: Yper Hall, Joanna Bacon, Philip Marsh
-
Publication number: 20180066044Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.Type: ApplicationFiled: July 27, 2017Publication date: March 8, 2018Inventors: Heinz HILLEN, Stefan BARGHORN, Boris LABKOVSKY, Ulrich EBERT, Andreas STRIEBINGER, Patrick KELLER
-
Publication number: 20180066045Abstract: The invention provides IGFBP7 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.Type: ApplicationFiled: November 20, 2017Publication date: March 8, 2018Applicant: ASTUTE MEDICAL, INC.Inventors: Ravi A. VIJAYENDRAN, Srivatsa VENKATASUBBARAO
-
Publication number: 20180066046Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat rheumatoid arthritis.Type: ApplicationFiled: September 14, 2017Publication date: March 8, 2018Inventor: Jeffrey T.L. Smith
-
Publication number: 20180066047Abstract: The present invention relates to methods of making human anti-HMGB1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions in HMGB1 associated-neuropathy.Type: ApplicationFiled: October 31, 2017Publication date: March 8, 2018Inventors: Li-Te CHIN, Shu-Ching HSU, Kai-Chen WANG
-
Publication number: 20180066048Abstract: The invention relates to a multiple-variable dose method for treating a disorder in which TNF? activity is detrimental, comprising administering to a subject in need thereof a first induction dose of an anti-TNF? antibody which ranges from 161 to 320 mg such that a threshold level of TNF? inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNF? inhibitor within a treatment phase, such that treatment occursType: ApplicationFiled: April 8, 2016Publication date: March 8, 2018Inventors: Rachel Moodie, Elizabeth Hyland
-
Publication number: 20180066049Abstract: Tumor Necrosis Factor-? (TNF?) promotes an inflammatory response resulting in many clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma. Dysregulation of TNF production is implicated in a variety of human diseases including Alzheimer's disease, cancer, major depression, and inflammatory bowel disease. These disorders are treated with a TNF? inhibitor.Type: ApplicationFiled: August 9, 2017Publication date: March 8, 2018Inventors: Rajiv Datar, Carl K. Edwards, III, Scott M. Brown
-
Publication number: 20180066050Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.Type: ApplicationFiled: November 1, 2017Publication date: March 8, 2018Inventors: Yue Yao, Janine M. Bilsborough
-
Publication number: 20180066051Abstract: The invention relates generally to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.Type: ApplicationFiled: November 20, 2017Publication date: March 8, 2018Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
-
Publication number: 20180066052Abstract: The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females.Type: ApplicationFiled: August 7, 2017Publication date: March 8, 2018Applicant: University of Virginia Patent FoundationInventors: John C. Herr, Monika Sachdev, Arabinda Mandal
-
Publication number: 20180066053Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: April 18, 2017Publication date: March 8, 2018Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer Widger
-
Publication number: 20180066054Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention.Type: ApplicationFiled: October 11, 2017Publication date: March 8, 2018Inventors: Kent B. THUDIUM, Mark J. SELBY, Kyra D. ZENS, Mark YAMANAKA, Alan J. KORMAN, Heidi N. LeBlanc
-
Publication number: 20180066055Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: ApplicationFiled: November 20, 2017Publication date: March 8, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
-
Publication number: 20180066056Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.Type: ApplicationFiled: September 19, 2017Publication date: March 8, 2018Applicants: MEDIMMUNE, LLC, THE JOHNS HOPKINS UNIVERSITYInventors: SOLOMON LANGERMANN, LINDA LIU, SHENG YAO, LIEPING CHEN
-
Publication number: 20180066057Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.Type: ApplicationFiled: October 27, 2017Publication date: March 8, 2018Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
-
Publication number: 20180066058Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.Type: ApplicationFiled: September 7, 2017Publication date: March 8, 2018Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen D. GILLIES
-
Publication number: 20180066059Abstract: Antibodies, chimeric antigen receptors, and bispecific T-cell engagers having specificity for B7-H6 and methods for using the same in the diagnosis and treatment of disorders associated with B7-H6 expression are provided.Type: ApplicationFiled: October 16, 2017Publication date: March 8, 2018Inventors: Charles L. SENTMAN, Tong ZHANG
-
Publication number: 20180066060Abstract: The invention relates to a cell line expressing the gamma chain of the Fc?RI receptor and human CD303 antigen, characterised in that said cell line is transfected in a stable manner by an expression vector comprising a nucleic acid molecule coding for human CD303 antigen and having strong expression of human CD303 on the surface thereof, e.g. at least 10000 molecules of human CD303 per cell, as well as a vector or vector kit that can be used to co-express the gamma chain of the Fc?RI receptor and human CD303 antigen, and different uses of the cell line of the invention.Type: ApplicationFiled: March 31, 2016Publication date: March 8, 2018Applicant: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Nathalie FOURNIER, Christophe DE ROMEUF
-
Publication number: 20180066061Abstract: The disclosure relates to the treatment of sporadic inclusion body myositis and other muscle wasting disorders with novel regimens, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an ActRII receptor binding molecule, an ActRII receptor antibody, such as the bimagrumab antibody.Type: ApplicationFiled: September 28, 2017Publication date: March 8, 2018Inventors: Dimitris Papanicolaou, Ronenn Roubenoff, Brian Tseng, Charles Gubser, David Glass
-
Publication number: 20180066062Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.Type: ApplicationFiled: November 13, 2017Publication date: March 8, 2018Applicant: The University of MelbourneInventors: John Allan Hamilton, Andrew David Cook
-
Publication number: 20180066063Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.Type: ApplicationFiled: June 9, 2017Publication date: March 8, 2018Inventors: Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George F. Widhopf, II, Charles Prussak
-
Publication number: 20180066064Abstract: Prostate cancer (PCa) is typically associated with genetic alterations involving androgen sensitivity and the androgen receptor (AR). Described herein is the expression, molecular regulation, subcellular localization and functional role of a G-protein coupled receptor, GPR158, wherein different four human PCa cell lines with variable alterations in the AR result in various degrees of androgen-responsiveness, androgen-sensitivity and AR expression. Elevation of GPR158 expression is an important oncogenic event that stimulates PCa cell proliferation and progression and thus GPR158 may represent an innovative therapeutic target, particularly for prevent and management of advanced stage PCa, such as castration-resistant prostate cancer (CRPC).Type: ApplicationFiled: February 16, 2016Publication date: March 8, 2018Applicant: University of Southern CaliforniaInventor: M. Elizabeth Fini
-
Publication number: 20180066065Abstract: Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant 5 tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by coadministering an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK/PI3 kinase/AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and/or vi) an effective amount of trastuzumab or T-DM 1, and/or combinations thereof; and an effective amount of a 10 bispecific anti-ErbB2/anti-ErbB3 antibody.Type: ApplicationFiled: June 22, 2017Publication date: March 8, 2018Inventors: Bo ZHANG, Charlotte MCDONAGH, Alexandra HUHALOV
-
Publication number: 20180066066Abstract: Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.Type: ApplicationFiled: July 7, 2017Publication date: March 8, 2018Inventors: Ningyan ZHANG, Zhiqiang AN
-
Publication number: 20180066067Abstract: The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of ?-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.Type: ApplicationFiled: March 17, 2016Publication date: March 8, 2018Applicant: NOVARTIS AGInventors: Feng CONG, Huaixiang HAO, Lloyd B. KLICKSTEIN, Rou-Fun KWONG, Ann TAYLOR, Yang XIE
-
Publication number: 20180066068Abstract: The invention relates to antibody molecules which bind pSYK, and methods for using the same for diagnosis, prognosis, to select patients for treatment with a SYK-targeted therapy, or evaluate the pharmacodynamic profile of a SYK-targeted therapy.Type: ApplicationFiled: April 21, 2015Publication date: March 8, 2018Inventors: Rachael L. BRAKE, Anne L. BURKHARDT, Helen D. HE MCDOUGALL, Karuppiah KANNAN, Matthew THEISEN, Stephen M. TIRRELL
-
Publication number: 20180066069Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.Type: ApplicationFiled: September 13, 2017Publication date: March 8, 2018Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar